Viatris Inc. (VTRS) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

16/25

Growth 4 Margin 3 Expansion 4 Platform 0 Financial 5

latest quarter score

Earnings Reports

16
Viatris (VTRS) Q2 2026: Greater China Delivers Low Double-Digit Growth, Offsetting Supply and Policy Headwinds
August 07, 2026
20
Viatris (VTRS) Q1 2026: Greater China Surges 18%, E-Commerce and Pipeline Propel Growth Narrative
May 07, 2026
15
Viatris (VTRS) Q4 2025: $650M Cost Overhaul Sets Stage for Sustainable Margin Expansion
February 26, 2026
10
Viatris (VTRS) Q3 2025: $920M Capital Return Signals Strategic Cost Review and Pipeline Transition
November 06, 2025
13
Viatris (VTRS) Q2 2025: $350M Buybacks Signal Commitment to Shareholder Returns Amid Pipeline Momentum
August 07, 2025
12
Viatris (VTRS) Q1 2025: $2.9B Goodwill Impairment Underscores Volatility, Pipeline and Buybacks Counterbalance Headwinds
July 07, 2025

Browse all companies